Summary
Epstein–Barr virus (EBV) expression was investigated by immunohistochemistry (latent membrane protein 1 [LMP-1]) and in situ hybridization (EBV encoded RNA [EBER]) in biopsies from 95 patients with untreated Hodgkin’s disease (HD). Tumour EBV status was related to EBV antibody titres, spontaneous and concanavallin A induced blood lymphocyte DNA synthesis, serum levels of soluble (s) CD4, sCD8, sCD25, sCD30, sCD54, β2-microglobulin, thymidine-kinase, routine chemistry, patient characteristics, complete remission and survival. The median follow-up time was 145 months (range 60–257). Tumour EBV-positive (n = 30; 33%) and negative (n = 62; 67%) patients did not differ with regard to sex, age, stage, presence of bulky disease or B-symptoms, remission rate or survival. The proportion of EBV+ cases was significantly higher among patients with mixed cellularity histopathology (58%) as compared to the nodular sclerosis subtype (18%; P < 0.001). The total white blood cell (WBC) counts were significantly lower in EBV+ patients (P < 0.01), who also had significantly higher levels of sCD54 (P < 0.02) and a tendency towards lower levels of sCD30 (P = 0.056). Patients in the tumour EBV+ group had significantly higher IgG antibody titres to restricted early antigen (EA-R) (P < 0.02). Hence, clinical features and outcome were not related to tumour EBV status. However, HD patients with EBV+ tumours had elevated sCD54 levels, higher antibody titres to EA-R and decreased total WBC counts. A potential causal relationship between EBV tumour status and these findings needs to be further explored.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Armitage, P & Berry, G (1987). Statistical Methods in Medical Research, 2nd edn Blackwell: Cambridge 125–132.
Axdorph, U, Grimfors, G, Landgren, O, Giscombe, R, Johansson, B & Björkholm, M (1995). Serum levels of sICAM-1 are correlated to tumour burden and blood lymphocyte functions in untreated Hodgkin’s disease. Third International Symposium on Hodgkin’s Lymphoma, Köln (abstract),
Bibeau, F, Brousset, P, Knecht, H, Meggetto, F, Drouet, E, Rubin, B & Delsol, G (1994). Epstein–Barr virus replication in Hodgkin’s disease. Bull Cancer 81: 114–118.
Björkholm, M, Holm, G, Mellstedt, H, Johansson, B & Askergren, J (1977). Prognostic factors in Hodgkin’s disease. I. Analysis of histopathology, stage distribution and results of therapy. Scand J Haematol 19: 487–495.
Björkholm, M, Holm, G, Mellstedt, H, Johansson, B, Killander, D, Sundblad, R & Söderberg, G (1978). Prognostic factors in Hodgkin’s disease. II. The role of lymphocyte defect. Scand J Haematol 20: 306–308.
Björkholm, M, Axdorph, U, Grimfors, G, Merk, K, Johansson, B, Svedmyr, E, Mellstedt, H & Holm, G (1995). Fixed versus response adapted MOPP/ABVD chemotherapy in Hodgkin’s disease. Ann Oncol 6: 895–899.
Brousset, P, Knecht, H, Rubin, B, Drouet, E, Chittal, S, Meggetto, F, Saati, TA, Bachmann, E, Denoyel, G, Sergeant, A & Delsol, G (1993). Demonstration of Epstein-Barr virus replication in Reed-Sternberg cells of Hodgkin’s disease. Blood 82: 872–876.
Carbone, PP, Kaplan, HS, Musshoff, K, Smithers, DW & Tubiana, M (1971). Report of the Committee on Hodgkin’s disease staging classification. Cancer Res 31: 1860–1861.
Cordell, JL, Falini, B, Erber, WN, Ghosh, AK, Abdulaziz, Z, MacDonald, S, Pulford, KA, Stein, H & Mason, DY (1984). Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32: 219
Dougherty, G, Murdoch, S & Hogg, N (1988). The function of human intercellular adhesion molecule-1 (ICAM-1) in the generation of an immune response. Eur J Immunol 18: 35–39.
Enblad, G, Sandvej, K, Lennette, E, Sundström, C, Klein, G, Glimelius, B & Pallesen, G (1997). Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed–Sternberg cells of patients with Hodgkin’s disease. Int J Cancer 72: 394–397.
Frisan, T, Sjöberg, J, Dolcetti, R, Boiocchi, M, de Re, V, Carbone, A, Brautbar, C, Battat, S, Biberfeld, P, Ekman, M, Christensson, B, Sundström, C, Björkholm, M, Pisa, P & Masucci, MG (1995). Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin’s disease. Blood 86: 1493–1501.
Grimfors, G, Andersson, B, Tullgren, O, Giscombe, R, Holm, G, Johansson, B & Björkholm, M (1992). Increased serum CD 8 soluble antigen level is associated with blood lymphocyte abnormalities and other established indicators of poor prognosis in adult Hodgkin’s disease. Br J Haematol 80: 166–171.
Groux, H, Bigler, M, de Vries, JE & Roncarolo, MG (1996). Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med 184: 19–29.
Gruss, HJ & Hermann, F (1996). CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control for CD30+ lymphoid and lymphoma cells. Leukemia and Lymphoma 20: 397–409.
Gruss, HJ, Scheffran, I, Hubinger, G, Duyster, J & Herrman, F (1996). The CD30 ligand and CD40 ligand regulate CD54 surface expression and release of its soluble form by cultured Hodgkin and Reed–Sternberg cells. Leukemia 10: 829–835.
Harris, LN (1995). A practical approach to the pathology of lymphoid neoplasms: a revised European–American classification from the international lymphoma study group. In: Important Advances in Oncology, De Vita Hellman Rosenberg (eds), pp. 111–140. JB Lippincott: Philadelphia
Henle, W, Henle, GE & Horwitz, CA (1974). Epstein-Barr virus specific diagnostic tests in infectious mononucleosis. Hum Pathol 5: 551–565.
Herbst, H, Dallenbach, F, Hummel, M, Niedobitek, G, Pileri, S, Muller-Lantsch, N & Stein, H (1991). Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci USA 88: 4766–4770.
Herbst, H, Foss, HD, Samol, J, Araujo, I, Klotzbach, H, Krause, H, Agathanggelou, A, Niedobitek, G & Stein, H (1996). Frequent expression of interleukin-10 in Epstein-Barr virus-harboring tumour cells of Hodgkin’s disease. Blood 87: 2918–2929.
Kaczorowski, S, Kaczorowska, M & Christensson, B (1994). Expression of EBV encoded latent membrane protein 1 (LMP-1) and bcl-2 protein in childhood and adult Hodgkin’s disease: application of microwave irradiation for antigen retrival. Leukemia Lymphoma 13: 273–283.
Kanavaros, P, Jiwa, M, van der Valk, P, Walboomers, J, Horstman, A & Meijer, C (1993). Expression of Epstein-Barr virus latent gene products and related cellular activation and adhesion molecules in Hodgkin’s disease and non-Hodgkin’s lymphomas arising in patients without overt pre-existing immunodeficiency. Hum Pathol 24: 725–729.
Khanna, R, Burrows, SR, Nicholls, J & Poulsen, LM (1998). Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP 1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP 1-specific cytotoxic T lymphocytes. Eur J Immunol 28: 451–458.
Knecht, H, McQuain, C, Martin, J, Rothenberger, S, Drexler, HG, Berger, C, Bachmann, E, Kittler, ELW, Odermatt, BF & Quesenberry, PJ (1996). Expression of the LMP1 oncoprotein in the EBV-negative Hodgkin’s disease cell line L-428 is associated with Reed-Sternberg cell morphology. Oncogene 13: 947–953.
Lauritzen, AF, Hörding, U & Nielsen, HW (1994). Epstein-Barr virus and Hodgkin’s disease: a comparative immunological, in situ hybridization, and polymerase chain reaction study. APMIS 102: 495–500.
Levine, PH, Pallesen, G, Ebbesen, P, Harris, N, Evans, AS & Mueller, N (1994). Evaluation of Epstein-Barr virus antibody patterns and detection of viral markers in the biopsies of patients with Hodgkin’s disease. Int J Cancer 59: 48–50.
MacLennan, KA, Bennett, MH, Tu, A, Vaughan Hudson, B, Easterling, J, Vaughan Hudson, G & Jelliffe, AM (1989). Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin’s disease. Cancer 64: 1686–1693.
Makgoba, MW, Sanders, ME, Ginther Luce, GE, Dustin, ML, Springer, TA, Clark, EA, Mannoni, P & Shaw, S (1988a). ICAM-1 a ligand for LFA-1-dependent adhesion of B, T and myeloid cells. Nature 331: 86–88.
Makgoba, MW, Sanders, ME, Ginther Luce, GE, Gugel, EA, Dustin, ML, Springer, TA & Shaw, S (1988b). Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1-dependent adhesion in T cell-mediated cytotoxicity. Eur J Immunol 18: 637–640.
Marlin, SD & Springer, TA (1987). Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell 51: 813–819.
Mehta, CR, Patel, NR & Tsiatis, AA (1984). Exact significance testing to establish treatment equivalence for ordered categorial data. Biometrics 40: 819–825.
Merk, K, Lennette, E, Holm, G, Johansson, B, Klein, G & Björkholm, M (1992). Antibodies to Epstein-Barr virus in relation to clinical characteristics of untreated patients with Hodgkin’s disease (paper 5). In: An Epidemiological Approach to the Etiology of Hodgkin’s Disease. Thesis, Karl Merk, Department of Oncology, Karolinska Institute: Stockholm
Morente, MM, Piris, MA, Abraira, V, Acevedo, A, Aguilera, B, Bellas, C, Fraga, M, Garcia-Del-Moral, R, Gomez-Marcos, F, Menarguez, J, Oliva, H, Sanchez-Beato, M & Montalban, C (1997). Adverse clinical outcome in Hodgkin’s disease is associated with loss of retinoblastoma protein expression, high Ki-67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression. Blood 90: 2429–2436.
Mueller, N, Evans, A, Harris, NL, Comstock, GW, Jellum, E, Magnus, K, Orentreich, N, Polk, F & Vogelman, J (1989). Hodgkin’s disease and Epstein-Barr virus altered antibody pattern before diagnosis. N Engl J Med 320: 689–695.
Murray, RJ, Wang, D, Young, LS, Wang, F, Rowe, M, Kieff, E & Rickinson, AB (1988). Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP. J Virol 62: 3747–3755.
Nadali, G, Vinante, F, Ambrosetti, A, Todeschini, G, Veneri, D, Zanotti, R, Meneghini, V, Ricetti, MM, Benedetti, F, Vassanelli, A, Perona, G, Chilosi, M, Menestrina, F, Fiacchini, M, Stein, H & Pizzolo, G (1994). Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin’s disease and correlate with clinical features and prognosis. J Clin Oncol 12: 793–797.
Nakagomi, H, Dolcetti, R, Bejarano, MT, Pisa, P, Kiessling, R & Masucci, MG (1994). The Epstein-Barr virus latent membrane protein-1 (LMP-1) induces interleukin 10 production in Burkitt lymphoma lines. Int J Cancer 57: 240–244.
Pallesen, G, Hamilton-Dutoit, JS, Rowe, M & Young, LS (1991). Expression of Epstein-Barr virus (EBV) latent gene products in tumour cells of Hodgkin’s disease. Lancet 337: 320–322.
Pinkus, GS, Lones, M, Shintaku, P & Sad, JW (1994). Immunohistochemical detection of Epstein-Barr virus-encoded latent membrane protein in Reed–Sternberg cells and variants of Hodgkin’s disease. Modern Pathol 7: 454–461.
Pizzolo, G, Vinante, F, Nadali, G, Ricetti, MM, Morosato, L, Marrocchella, R, Vincenzi, C, Semenzato, G & Chilosi, M (1993). ICAM-1 tissue overexpression associated with increased serum levels of its soluble form in Hodgkin’s disease. Br J Haematol 84: 161–162.
Reedman, BM & Klein, G (1973). Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer 11: 499–520.
Sandvej, KB, Hamilton-Dutoit, SJ & Pallesen, G (1993). Influence of Epstein-Barr virus encoded latent membrane protein 1 on the expression of CD23 antigen, CD54 and LFA-3 in Hodgkin and Reed–Sternberg cells. A morphometric analysis. Leukemia Lymphoma 9: 95–101.
Tullgren, O, Grimfors, G, Holm, G, Johansson, B, Svedmyr, E, Wedelin, C, Mellstedt, H, Merk, K & Björkholm, M (1991). Lymphocyte abnormalities predicting a poor prognosis in Hodgkin’s disease. Cancer 68: 768–775.
Vestlev, PM, Pallesen, G, Sandvej, K, Hamilton-Dutoit, SJ & Bendtzen, SM (1992). Prognosis of Hodgkin’s disease is not influenced by Epstein-Barr virus latent protein. Int J Cancer 50: 670–671.
Wang, D, Liebowitz, D & Kieff, E (1985). An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43: 831–840.
Wang, D, Liebowitz, D, Wang, F, Gregory, C, Rickinson, A, Larson, R, Springer, T & Kieff, E (1988). Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol 62: 4173–4184.
Wedelin, C, Björkholm, M, Holm, G, Ogenstad, S, Johansson, B & Mellstedt, H (1982). Lymphocyte function in untreated Hodgkin’s disease: an important predictor of prognosis. Br J Cancer 45: 70–79.
Wu, TC, Mann, RB, Epstein, JI, MacMahon, E, Lee, WA, Charache, P, Hayward, SD, Kurman, RJ, Hayward, GS & Ambinder, RF (1991). Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. Am J Pathol 138: 1461–1469.
Younes, A, Consoli, U, Snell, V, Clodi, K, Kliche, KO, Palmer, JL, Gruss, HJ, Armitage, R, Thomas, EK, Cabanillas, F & Andreeff, M (1997). CD30 ligand in lymphoma patients with CD30+ tumours. J Clin Oncol 15: 3355–3362.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Axdorph, U., Porwit-MacDonald, A., Sjöberg, J. et al. Epstein–Barr virus expression in Hodgkin’s disease in relation to patient characteristics, serum factors and blood lymphocyte function. Br J Cancer 81, 1182–1187 (1999). https://doi.org/10.1038/sj.bjc.6690827
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690827
Keywords
This article is cited by
-
A Collaborative Nationwide Lymphoma Study in Lebanon: Incidence of Various Subtypes and Analysis of Associations with Viruses
Pathology & Oncology Research (2013)
-
Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin's lymphoma
British Journal of Cancer (2009)
-
The effect of Epstein–Barr virus status on clinical outcome in Hodgkin’s lymphoma
Annals of Hematology (2006)